ConductScience.org, home

Paper37653142

Clinical and translational advances in ovarian cancer therapy.

Konstantinopoulos PA and 1 other. Nat Cancer, 2023. Cited by 356 papers, by iCite.

Cite this record

ConductScience Library. Clinical and translational advances in ovarian cancer therapy. Papers, record 37653142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37653142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical and translational advances in ovarian cancer therapy.
PubMed
Journal
Nat Cancer
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
356
iCite
Relative citation ratio, by iCite
34.6
iCite
Revised in PubMed
2024-09-17
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Konstantinopoulos PAPanagiotis Ahttps://orcid.org/0000-0002-1032-1479
2Matulonis UAUrsula A

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
Humans
Female
Carcinoma, Ovarian Epithelial
Platinum

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA006516NCI NIH HHSUnited StatesP30CA006516PubMed and NIHNIH RePORTER
R01 CA258553NCI NIH HHSUnited StatesR01CA258553PubMed and NIHNIH RePORTER
P50CA240243NIHNIH RePORTER

Download CSV of grants

References157

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
235090748European cancer mortality predictions for the year 2022 with focus on ovarian cancer.Ann Oncol2022https://conductscience.org/library/papers/35090748PubMed
335020204Cancer statistics, 2022.CA Cancer J Clin2022https://conductscience.org/library/papers/35020204PubMed
435606067The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Gynecol Oncol2022https://conductscience.org/library/papers/35606067PubMed
533020491Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.Nat Commun2020https://conductscience.org/library/papers/33020491PubMed
620826764Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.Science2010https://conductscience.org/library/papers/20826764PubMed
726463832Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.Cancer Discov2015https://conductscience.org/library/papers/26463832PubMed
830917260Mucinous Ovarian Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/30917260PubMed
931335355p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.Am J Surg Pathol2019https://conductscience.org/library/papers/31335355PubMed
1026720728Inherited Mutations in Women With Ovarian Carcinoma.JAMA Oncol2016https://conductscience.org/library/papers/26720728PubMed
1136075393NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.J Natl Compr Canc Netw2022https://conductscience.org/library/papers/36075393PubMed
1231986064Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.J Clin Oncol2020https://conductscience.org/library/papers/31986064PubMed
1335715633Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.Br J Cancer2022https://conductscience.org/library/papers/35715633PubMed
1431672974Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.Nat Commun2019https://conductscience.org/library/papers/31672974PubMed
1522343227Symptoms associated with ovarian cancer.Clin Obstet Gynecol2012https://conductscience.org/library/papers/22343227PubMed
1624219974Staging classification for cancer of the ovary, fallopian tube, and peritoneum.Int J Gynaecol Obstet2014https://conductscience.org/library/papers/24219974PubMed
1734328210Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/34328210PubMed
1820833283Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?Gynecol Oncol2010https://conductscience.org/library/papers/20833283PubMed
1927502591Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol2016https://conductscience.org/library/papers/27502591PubMed
2035690073
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol2022https://conductscience.org/library/papers/35690073PubMed

See all 157 referencesDownload CSV of references

Cited by276

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 356 citations.

PMIDTitleJournalYearIn PapersSource
42985462Ovarian Carcinoma: Signal Pathways and Clinical Studies.MedComm (2020)2026https://conductscience.org/library/papers/42985462PubMed
42968661Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.Clin Transl Med2026https://conductscience.org/library/papers/42968661PubMed
42965079Near-Infrared Light-Responsive Liposomes for Modulating Switchable CAR-T Cell Therapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42965079PubMed
42959417The dual role of autophagy in gynecologic malignancies: promoting and inhibiting.Front Cell Dev Biol2026https://conductscience.org/library/papers/42959417PubMed
42922966Differential sparse attention framework for accurate ovarian cancer subtype classification using DenseNet121.Front Digit Health2026https://conductscience.org/library/papers/42922966PubMed
42909065Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models.Front Immunol2026https://conductscience.org/library/papers/42909065PubMed
42883230Phytochemical Profiles and Anticancer Activity of the Three Prosopis Species Growing in Qatar Against Lung and Ovarian Cancer Cells.Molecules2026https://conductscience.org/library/papers/42883230PubMed
42870871Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage.Transl Cancer Res2026https://conductscience.org/library/papers/42870871PubMed
42850290HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer.NPJ Precis Oncol2026https://conductscience.org/library/papers/42850290PubMed
42844251CYBRD1 is transcriptionally regulated by RUNX1 and mediates JAK2/STAT3 signaling activation during ovarian cancer progression.Oncogenesis2026https://conductscience.org/library/papers/42844251PubMed
42789557BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line.PLoS One2026https://conductscience.org/library/papers/42789557PubMed
42769152Ovarian cancer proteomic landscape changes across different pathological stages and biomarker-sets identified with integrative multiomics analysis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42769152PubMed
42753071Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.Inflammopharmacology2026https://conductscience.org/library/papers/42753071PubMed
42729152Integrative network toxicology and molecular docking reveal epigenetic and endocrine-disrupting mechanisms of PFAS in ovarian cancer.Front Pharmacol2026https://conductscience.org/library/papers/42729152PubMed
42650243Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women.Antioxidants (Basel)2026https://conductscience.org/library/papers/42650243PubMed
42630491Ovarian Cancer Stem Cells: Mechanisms of Progression and Therapeutic Strategies.Oncol Res2026https://conductscience.org/library/papers/42630491PubMed
42609197Rising Ovarian Cancer Burden in Africa, 2009-2023: Epidemiological Change, Age-Specific Patterns, COVID-19-Related Deviations, and Future Forecasts.Int J Womens Health2026https://conductscience.org/library/papers/42609197PubMed
42601376The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages.NPJ Precis Oncol2026https://conductscience.org/library/papers/42601376PubMed
42541248Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics.Genes Dis2026https://conductscience.org/library/papers/42541248PubMed
42532631Cancer-associated mesothelial cells drive immune escape and therapy resistance in ovarian cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42532631PubMed

See all 276 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37653142

GET https://conductscience.org/api/papers/v1/37653142/references?page=2